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Abstract: A close epidemiological link has been reported between cannabis use and schizophrenia
(SCZ). However, biochemical markers in living humans related to the impact of cannabis in this
disease are still missing. Olfactory neuroepithelium (ON) cells express neural features and offer
a unique advantage to study biomarkers of psychiatric diseases. The aim of our study was to
find exclusively deregulated proteins in ON cells of SCZ patients with and without a history of
cannabis use. Thus, we compared the proteomic profiles of SCZ non-cannabis users (SCZ/nc) and
SCZ cannabis users (SCZ/c) with control subjects non-cannabis users (C/nc) and control cannabis
users (C/c). The results revealed that the main cascades affected in SCZ/nc were cell cycle, DNA
replication, signal transduction and protein localization. Conversely, cannabis use in SCZ patients
induced specific alterations in metabolism of RNA and metabolism of proteins. The levels of targeted
proteins in each population were then correlated with cognitive performance and clinical scores. In
SCZ/c, the expression levels of 2 proteins involved in the metabolism of RNA (MTREX and ZNF326)
correlated with several cognitive markers and clinical signs. Moreover, use duration of cannabis
negatively correlated with ZNF326 expression. These findings indicate that RNA-related proteins
might be relevant to understand the influence of cannabis use on SCZ.
Keywords: cannabis; schizophrenia; proteomics; olfactory neuroepithelium; metabolism; RNA;
ZNF326; MTREX
1. Introduction
The complexity of schizophrenia (SCZ), involving intricate interactions between envi-
ronmental factors and genetics, hinders the identification of the molecular mechanisms
underlying its development [1]. State of the art techniques are being used to find biomark-
ers and ease clinical practice. In this sense, proteomic tools, allowing the study of a large
number of proteins at a time, can provide an integrated picture of the biological dysfunc-
tions associated with SCZ [2]. Serum, plasma and cerebrospinal fluid studies reveal an
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effect on proteins related to the innate immune system and a highly reported downreg-
ulation of Apolipoprotein A-I1 (APOA1) [3–5], which might mediate the impact of SCZ
on the peripheral immune response [6,7]. On the other hand, postmortem brain studies
have shown deregulations in metabolic pathways, calcium signalling and cytoskeleton
assembly in several brain areas in SCZ [8–10]. However, other neuropsychiatric condi-
tions present similar affectations [11]. In fact, the two most referenced biomarkers of SCZ,
namely Fructose-bisphosphate aldolase C (ALDOC) and Glial fibrillary acidic protein
(GFAP), are also altered in major depression and bipolar disorder [12]. Thus, postmortem
brains from individuals diagnosed with different mental conditions appear to have great
similarities that hamper the identification of exclusive biomarkers for SCZ. Additionally,
the impossibility of correlating these biochemical findings with cognitive dysfunctions
and environmental cues specific for each condition highlights the necessity to use other
substrates. In this context, the olfactory neuroepithelium (ON) has emerged as a useful
tool. This specialized epithelial tissue can be easily obtained from living subjects and it
contains multipotent progenitors that express neural markers [13–16]. Therefore, the main
advantage of ON cells is that ongoing environmental factors and molecular alterations can
be evaluated during the progression of the disease.
Years of epidemiological research in psychotic disorders suggest that cannabis use
is a specific environmental factor for SCZ. The incidence of cannabis use is two to four
times higher among SCZ patients, and its consumption doubles the risk of psychosis
in a dose- and time-dependent manner [17,18]. Moreover, an endocannabinoid system
imbalance, including alterations in the expression of the cannabinoid receptor 1 (CB1) in
postmortem brains and a diminished production of the enzymes involved in the synthesis
of endocannabinoids, has been observed in postmortem and peripheral samples of SCZ
patients [19,20]. Additionally, cannabis and SCZ have a shared effect on some cellular func-
tions. Indeed, protein metabolism via AKT/mTOR, cytoskeleton organization, and calcium
signalling are affected in human samples from SCZ patients [2], and after cannabinoid ex-
posure in cultured cells [21,22] and mice models [23,24]. Moreover, plasmatic samples from
heavy cannabis users and SCZ patients share an effect on oxidative stress response [7,25].
However, whether the coexistence of both factors has equal or distinct consequences is less
clear. In fact, in a synchrotron-based infrared spectroscopy study, significant differences
in the protein spectra were reported in ON cells from SCZ cannabis users compared to
non-users [26]. Additionally, we recently demonstrated that the functional signature of
the CB1 and serotonin 2A receptor (CB1-5HT2AR) heteromer in ON cells is differentially
regulated in SCZ patients depending on cannabis use [27].
Therefore, the aim of this study was to find exclusively deregulated proteins in ON
cells of SCZ patients with and without a history of chronic cannabis use. We applied
mass spectrometry-based quantitative proteomics followed by a functional analysis to
characterize the proteomic changes specifically induced by cannabis use in ON cells from
SCZ patients, as compared to controls that use cannabis or not. The primary outcome of
the study, i.e., the expression levels of the target proteins, were correlated with cannabis
consumption, and with secondary cognitive and clinical outcomes associated with SCZ.
2. Materials and Methods
2.1. Study Design
SCZ patients without a history of chronic cannabis use (SCZ/nc, n = 5), SCZ pa-
tients with a reported history of chronic cannabis use (SCZ/c, n = 5), chronic cannabis
users without any psychiatric diagnosis (C/c, n = 5), and control subjects non-cannabis
users (C/nc, n = 5) between 18 and 45 years old (both males and females), were recruited
to conduct a cross-sectional study. Every subject gave written informed consent after a
complete description of the study and the procedures involved. Cannabis users had to
consume more than 5 cannabis cigarettes per week during at least 6 months. On the day of
testing, subjects were told to refrain from cannabis use for at least 12 h before testing to
avoid the potential confounding of acute cannabis intoxication in both neuropsychological
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and proteomic studies. The exclusion criteria were: (i) meeting criteria for any severe
mental disorder according to the Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5); (ii) history of severe mental illness among first degree relatives;
(iii) history of severe congenital, medical or neurological illness; (iv) show medical condi-
tions with nasal repercussions (rhinitis or bleeding); and (v) use of other drugs of abuse.
SCZ-diagnosed participants were receiving antipsychotic medication at the time of the
study. All subjects underwent a physical, psychiatric and neuropsychological evaluation,
as previously described [16]. This study was approved by the local Institutional ethics
committee (CEIC-PSMAR).
2.2. Clinical and Neuropsychological Evaluation
Neuropsychological assessments were carried out in all subjects. Executive functions
were tested with the semantic verbal fluency test. Attention performance was evaluated
using the direct spatial span (SSP) and digit direct series. Working memory was addressed
using the inverse spatial span and digit inverse series using the Cambridge neuropsycho-
logical test automated battery (CANTAB 2017), and the digit span of the Wechsler Adult
Intelligence Scale (WAIS-III). Emotional recognition was evaluated with the CANTAB
test. Clinical outcomes included the global assessment of functioning (GAF), and the
neurological soft signs (NSS) scores.
2.3. Quantification of Cannabis Metabolites
To estimate the amount of cannabis consumed by cannabis users, the plasma con-
centrations of its main non-psychoactive metabolite, namely, 11-nor-9-carboxy-∆-9-THC
(THC-COOH), were calculated. Briefly, 1 mL of plasma was transferred into a glass tube
and spiked with d3-∆-9-THC as the internal standard. A protein precipitation with 2 mL of
0.1% formic acid in acetonitrile was performed prior to a solid phase extraction with Oasis
Prime HLB 3 cm3, 60 mg column (Waters Co., Milford, MA, USA). The supernatant was
diluted with MilliQ water and loaded. Subsequently, 2 mL of 25% of methanol was added
twice. Elution was carried out twice with 2 mL of 90:10 acetonitrile:methanol (ACN:MeOH).
The organic phase was evaporated to dryness under a nitrogen stream at < 39 ◦C and <15
psi pressure. Analytes were reconstituted in 50 µL of 90:10 ACN:MeOH and 50 µL of MilliQ
water. Quantification of THC-COOH in plasma was performed using an Agilent 1200
series HPLC system (Agilent Technologies) coupled to a 6410 Triple Quadrupole LC-MS
(Agilent Technologies) mass spectrometer with an electrospray interface.
2.4. Nasal Exfoliation and Cell Culture
ON samples were obtained by nasal brushing. Samples from the middle and upper
turbinates were maintained in 250 µL of cold Dulbecco’s Modified Eagle Medium/Ham
F-12 (DMEM/F12) enriched with 10% FBS, 2% glutamine and 1% streptomycin–penicillin
(GibcoBRL), as previously described [27]. At 80% confluence, cells were expanded using
0.25% trypsin (GibcoBRL) and replated in 75 cm2 flasks. Then, cells were expanded until
passage four was reached and stored in liquid nitrogen with 20% FBS and 10% dimethyl
sulfoxide (Sigma-Aldrich, Madrid, Spain). The aliquots from all subjects (n = 20) were
unfrozen at the same time and harvested in 75 cm2 flasks under standard conditions using
enriched DMEM/F12 medium.
2.5. Quantitative Proteomics in ON Cells
Physical protein extraction was performed using sterile scrappers and PBS 1X. After
centrifugation, the pellet was kept frozen at −80 ◦C until homogenization using lysis
buffer (7 M urea, 2 M thiourea, and 50 mM DTT). The homogenates were then subjected
to in-solution digestion, peptide purification and reconstitution prior to mass spectro-
metric analysis (MS/MS). Data acquisition was performed as previously described [28]
using ProteinPilot v5.0 (Sciex) as a search engine, ParagonTM Algorithm (v.4.0.0.0) [29]
for database searching and a non-lineal fitting method to calculate the false discovery
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rate (FDR) (1% Global FDR or better). Data analysis was performed by sequential win-
dow acquisition of all theoretical mass spectra–mass spectrometry (SWATH-MS), and the
TripleTOF 5600+ mass-spectrometer was configured as previously described [30]. The
library generation-associated ProteinPilot group file was loaded into PeakView® 2.1 (Sciex),
and peaks from SWATH runs were extracted with a peptide confidence threshold of 99%
confidence (Unused Score ≥1.3) and FDR lower than 1%. ProteinPilot was used to ex-
tract the MS/MS spectra of the assigned peptides, and only proteins quantified with at
least two unique peptides were considered. For more detailed information about the
SWATH-MS library generation, please refer to the extended experimental procedures in
the Supplementary Information.
2.6. Pathway Analysis, Statistics and Bioinformatics
The peer-reviewed pathway database REACTOME [31] was used to functionally
characterize the proteomic alterations detected in every comparison. This database hi-
erarchically classifies cellular functions in 27 cascades. We established a 0.01 p-value
threshold, and the functional proteome results obtained were ordered based on their FDR.
All calculations were performed using SPSS (SPSS Inc., Chicago, IL, USA). Normality
and homoscedasticity for continuous variables were tested using Shapiro–Wilk W and
Levene tests. Demographic categorical variables were evaluated using Chi-squared tests
and continuous normally distributed variables were evaluated using one-way ANOVAs
followed by the least significance difference (LSD) post-hoc test. Neuropsychological calcu-
lations were corrected for tobacco use duration. Not normally distributed variables were
compared using Kruskal–Wallis and Dunn’s post-hoc test. Vulcano plot representations
and Spearman correlation plots were depicted using GraphPad prism 8.0 Software (La
Jolla California, CA, USA). Venn diagrams for proteomic comparisons were designed using
BioVenn platform [32].
3. Results
3.1. Demographics and Neuropsychological Outcomes
The demographic data are shown in Table 1. The groups did not differ in age, sex or
dosage of tobacco use. However, SCZ/c showed a significantly higher duration of tobacco
use (years) when compared to all other groups (p < 0.05). The analysis of cannabis use
patterns between C/c and SCZ/c revealed no significant differences. The neuropsychologi-
cal evaluation (Table 2) revealed significantly lower verbal fluency scores for SCZ/nc and
SCZ/c as compared to C/nc (p < 0.05), but not when compared to C/c. GAF scores were
significantly lower in SCZ/nc and SCZ/c when compared to C/nc and C/c (p < 0.001).
Finally, significantly more NSS were present in SCZ patients regardless of cannabis use
when compared to C/nc (p < 0.01) and C/c (p < 0.05).
3.2. Plasmatic Concentrations of THC-COOH
The plasmatic concentrations of THC-COOH were not significantly different between
the groups (C/c: 34.92 ± 17.55 ng/mL; SCZ/c: 11.22 ± 15.91 ng/mL).
3.3. Proteomic Analyses
Our proteomic workflow was fundamentally based on a triangular approach [33],
whereby a relatively small number of cases and controls are analyzed by hypothesis-free
discovery proteomics in great depth, leading to the quantification of thousands of proteins.
Using this workflow, we observed specific changes in protein abundance in C/nc vs. SCZ
patients and in SCZ/nc vs. SCZ/c, underpinning the importance of analyzing independent
factors (disease/cannabis), instead of merely contrasting SCZ versus control cases. Firstly,
C/c, SCZ/nc and SCZ/c were compared to C/nc subtracting exclusively deregulated
proteins for each population. Then, each group of SCZ patients was compared to C/c
to subtract the effect of cannabis use on control subjects. In the end, each group of SCZ
(SCZ/nc and SCZ/c) was compared to obtain proteomic biomarkers that were only affected
J. Pers. Med. 2021, 11, 160 5 of 15
by SCZ or by SCZ plus cannabis use. For the summary followed in the proteomic data
analysis, see Supplementary Figure S1.










Age (years) 31.4 ± 5.5 29.2 ± 5.6 37 ± 10.1 41.4 ± 6.2
Gender (M-F) 3/2 4/1 2/3 5/0
Tobacco use
Users—n (%) 5 (100%) 4 (80%) 4 (80%) 5 (100%)
Units per week µ 53.8 ± 50.2 36.4 ± 40.6 91.2 ± 91.0 147 ± 62.6
Use duration (years) µ 11.4 ± 4.9 10.4 ± 10.0 5.8 ± 6.8 24.2 ± 9.6 *,+,#
Cannabis use
Age first use (years) µ - 15.4 ± 2.5 - 17.2 ± 3
Units per week µ - 16.2 ± 10.2 - 19.4 ± 14.6
Use duration (years) µ - 12.2 ± 7.2 - 17.6 ± 11.5
Antipsychotic
treatment
Clozapine/Olanzapine - - 1/5 3/5
Aripiprazole - - 2/5 1/5
Paliperidone - - 1/5 1/5
Risperidone - - 1/5 -
Data are shown as mean ± SD. * p < 0.05 vs. C/nc; +p < 0.05 vs. C/c; # p < 0.05 vs. SCZ/nc. (µ) Indicates continuous non-normally
distributed variables.










Direct series score 8.8 ± 0.4 8.2 ± 1.8 7.4 ± 1.5 8.8 ± 2.2
Inverse series score µ 6.3 ± 1.3 8.2 ± 5.5 4.4 ± 1.5 8.8 ± 2.1
Verbal fluency score 26 ± 1.2 22.8 ± 4.5 18.8 ± 6.9 17.2 ± 5.3 *,+
Direct spatial span 7.4 ± 0.6 5.6 ± 1.9 5.2 ± 1.5 5.6 ± 1.7
Inverse spatial span 7.6 ± 2.9 5.8 ± 1.5 5.6 ± 3 5.6 ± 1.7
Emotional recognition 65.9 ± 8.6 73.8 ± 7.4 58.2 ± 22.5 58.9 ± 10.2
Global assessment of
functioning µ 99 ± 5 96 ± 5.5 67 ± 8.4 ***
,+,++ 63 ± 2.7 ***,+,++
Neurological soft signs µ 2.8 ± 1.1 5.2 ± 3.1 14.8 ± 8.6 **,+ 13.2 ± 2.3 **,+
Data are shown as mean ± SD of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001 versus C/nc; + p < 0.05; ++ p < 0.01 versus C/c. (µ) Indicates
continuous non-normally distributed variables.
3.3.1. Quantitative and Functional Proteomic Profile of ON Cells from SCZ Patients as
Compared to C/nc
The proteomic analysis of ON cells from C/c, SCZ/nc and SCZ/c as compared to
C/nc showed 1185, 1209 and 1584 deregulated proteins, respectively. The Venn diagrams
(Figure 1a) showed that in C/c, 550 proteins were upregulated (554 in SCZ/nc and 758
in SCZ/c). On the other hand, 635 proteins were downregulated in C/c (655 in SCZ/nc
and 826 in SCZ/c); 371 proteins were commonly upregulated in C/c, SCZ/nc and SCZ/c;
211 were exclusively upregulated in SCZ/c and 44 in SCZ/nc. In addition, 474 proteins
were commonly downregulated in C/c, SCZ/nc and SCZ/c; 169 were exclusively down-
regulated in SCZ/c and 37 in SCZ/nc. In total, 845 proteins were commonly deregulated
in C/c, SCZ/nc and SCZ/c as compared to C/nc. The pathway analysis of the 845 com-
monly deregulated proteins (Figure 1b) revealed programmed cell death (37 proteins;
log(10)FDR = 4.5), metabolism of proteins (225 proteins; log(10)FDR = 4.2), extracellular
matrix organization (47 proteins; log(10)FDR = 3.5), vesicle-mediated transport (87 proteins;
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log(10)FDR = 2.7), immune system (241 proteins; log(10)FDR = 2.0), protein localization
(22 proteins; log(10)FDR = 1.4) and cellular responses to external stimuli (67 proteins;
log(10)FDR = 1.2).




Figure 1. Characterization of the proteome of ON cells from control subjects non-cannabis users (C/nc), control cannabis 
users (C/c), schizophrenia patients non-cannabis users (SCZ/nc) and schizophrenia patients cannabis users (SCZ/c). (a) 
Proteomic alterations in C/c, SCZ/nc and SCZ/c as compared to C/nc. The upregulated and downregulated proteins in 
C/c-C/nc, SCZ/nc-C/nc and SCZ/c-C/nc are represented in two different Venn diagrams. (b) Enrichment pathway analysis 
of the 845 proteins commonly deregulated in C/c, SCZ/nc and SCZ/c as compared to C/nc. (c) Enrichment pathway 
analysis of the exclusively deregulated proteins in C/c, (d) SCZ/nc (e) and SCZ/c versus C/nc. (f) Proteomic alterations in 
SCZ/nc and SCZ/c as compared to C/c. The upregulated and downregulated proteins when SCZ/nc-C/c and SCZ/c-C/c 
are compared are represented in two Venn diagrams. (g) Functional characterization of the 43 proteins deregulated in 
SCZ/nc and the 154 proteins deregulated in SCZ/c as compared to C/c. (h) Functional characterization of the 115 proteins 
deregulated in SCZ/c as compared to SCZ/nc. Data from the pathway analysis are represented as minus the logarithm 
(10) of the FDR. 
  
Figure 1. Characterization of the proteome of ON cells from control subjects non-cannabis users (C/nc), control cannabis
users (C/c), schizophrenia patients non-cannabis users (SCZ/nc) and schizophrenia patients cannabis users (SCZ/c). (a)
Proteomic alterations in C/c, SCZ/nc and SCZ/c as compared to C/nc. The upregulated and downregulated proteins in
C/c-C/nc, SCZ/nc-C/nc and SCZ/c-C/nc are represented in two different Venn diagrams. (b) Enrichment pathway analysis
of the 845 proteins commonly deregulated in C/c, SCZ/nc and SCZ/c as compared to C/nc. (c) Enrichment pathway analysis
of the exclusively deregulated proteins in C/c, (d) SCZ/nc (e) and SCZ/c versus C/nc. (f) Proteomic alterations in S nc
and SCZ/c as compared to C/c. The upr gulated and downregulated proteins when SCZ/nc-C/c and SCZ/c-C/c are
compared are represented in two V nn diagrams. (g) Functional characterization of the 43 proteins deregulated in SCZ/nc
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and the 154 proteins deregulated in SCZ/c as compared to C/c. (h) Functional characterization of the 115 proteins
deregulated in SCZ/c as compared to SCZ/nc. Data from the pathway analysis are represented as minus the logarithm (10)
of the FDR.
The exclusive impact of cannabis on C/c was represented by 102 proteins (Figure 1c),
wherein the main pathways affected included the immune system (79 proteins; log(10)FDR
= 10.9), metabolism of RNA (21 proteins; log(10)FDR = 1.7), cellular responses to external
stimuli (19 proteins; log(10)FDR = 1.6) and protein localization (7 proteins; log(10)FDR = 1.4).
When comparing the two groups of SCZ vs. C/nc, we detected a substantial differ-
ence (Figure 1d). SCZ/nc only showed 81 exclusively deregulated proteins, whereas 380
were deregulated in SCZ/c. The functional characterization of the 81 proteins deregu-
lated in SCZ/nc indicated that most of them were involved in cell cycle (16 proteins;
log(10)FDR = 2.0), DNA replication (6 proteins; log(10)FDR = 1.7) and cellular responses
to external stimuli (11 proteins; log(10)FDR = 1.2). On the other hand, the 380 proteins
deregulated in SCZ/c (Figure 1e) were associated with metabolism of RNA (61 proteins;
log(10)FDR = 8.3), cellular responses to external stimuli (54 proteins; log(10)FDR = 7.1) and
metabolism of proteins (104 proteins; log(10)FDR = 2.8).
3.3.2. Quantitative and Functional Proteomic Profile of ON Cells from SCZ Patients as
Compared to C/nc
To identify disease-exclusive protein markers, and tease out the effect of cannabis
use, the exclusively deregulated proteins in SCZ/nc and SCZ/c were compared to C/c
(Figure 1f). In total, 53 proteins were deregulated in SCZ/nc, whereas 164 proteins were
differentially expressed in SCZ/c. In SCZ/nc, 30 proteins were upregulated and 101
in SCZ/c.
On the other hand, 23 proteins were downregulated in SCZ/nc and 63 in SCZ/c. The
Venn diagram revealed that only 10 proteins were commonly upregulated in SCZ/nc and
SCZ/c as compared to C/c, wherein none were commonly downregulated. The functional
characterization of the 43 exclusively deregulated proteins in SCZ/nc (Figure 1g) indicated
that signal transduction (2 proteins; log(10)FDR = 0.6) and protein localization (2 proteins;
log(10)FDR = 0.6) were the mainly enriched functions. The 154 exclusively deregulated
proteins in SCZ/c unveiled metabolism of RNA (21 proteins; log(10)FDR = 1.4) as the
only deregulated cascade. Thus, the profile of deregulated protein pathways in SCZ/c
patients as compared to C/c is quantitatively larger and functionally different to the
profile observed in SCZ/nc. To further evaluate the specific proteins involved SCZ/nc
vs. SCZ/c, we assessed their functional differences. The results showed that 115 proteins
were differentially expressed (Figure 1h). These proteins were associated with metabolism
of RNA (28 proteins; log(10)FDR = 7.6), cellular responses to external stimuli (27 proteins;
log(10)FDR = 7.2), metabolism of proteins (40 proteins; log(10)FDR = 2.7) and developmental
biology (25 proteins; log(10)FDR = 2.4). A detailed list of the proteins involved in each
comparison can be found in the Supplement Material.
3.3.3. Specific Proteins Markers of SCZ Depending on Cannabis Use
To identify specific protein markers in ON cells of SCZ/nc, we designed a Venn
diagram including the 81 proteins exclusively deregulated in SCZ/nc as compared to
C/nc; the 115 proteins differently expressed in SCZ/nc as compared to SCZ/c; and the 43
proteins exclusively different between SCZ/nc and C/c (Figure 2a). In total, 3 proteins were
commonly deregulated in these comparisons: (i) Cyclin-dependent-like kinase 5 (CDK5),
(ii) LSM2 Homolog, U6 Small Nuclear RNA and mRNA Degradation-Associated (LSM2),
and (iii) Tyrosine-tRNA ligase, mitochondrial (YARS2). The expression of CDK5 was
significantly reduced in SCZ/nc (p < 0.01) as compared to C/nc. In addition, a significant
increase in the expression of this protein was observed in SCZ/c when compared to
SCZ/nc (p < 0.01) (Figure 2b). LSM2 was downregulated in SCZ/nc as compared to C/nc
(p < 0.01) and vs. C/c (p < 0.01), and presented a different expression in SCZ/c vs. SCZ/nc
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(p < 0.01) (Figure 2c). YARS2 was significantly downregulated in SCZ/nc as compared to
C/c (p < 0.01), and vs. SCZ/c (p < 0.01) (Figure 2d).




Figure 2. Specific proteomic markers of schizophrenia patients non-cannabis users (SCZ/nc). (a) Venn diagram compar-
ing SCZ/nc to control subjects non-cannabis users (C/nc), control cannabis users (C/c) and schizophrenia patients canna-
bis users (SCZ/c). Graphical representation of CDK5 (b), LSM2 (c) and YARS2 (d), which were commonly deregulated in 
SCZ/c as compared to C/nc, C/c and SCZ/nc. ** p < 0.01; versus C/nc; ++ p < 0.01 versus C/c; ## p < 0.01 versus SCZ/nc. 
3.4. Correlations between Specific Protein Markers, Cannabis Use and Cognitive Performance 
A Spearman correlation plot was designed to evaluate the association between the 
expression levels of target proteins identified in SCZ/nc and in SCZ/c with cognitive 
performance, cannabis use patterns, and clinical signs in the entire population. For pro-
teins related to SCZ/nc, the results showed that higher LSM2 expression was correlated 
with better GAF (r = 0.50, p < 0.05) and less NSS (r = −0.54, p < 0.05), whereas higher 
YARS2 levels were associated with better attentional performance in the direct series 
score test (r = 0.53, p < 0.05) (Data not shown). For proteins related to SCZ/c, MYO1B 
negatively correlated with plasmatic THC-COOH concentration (r = −0.80, p < 0.05) (Fig-
ure 4a), and ZNF326 positively correlated with cannabis use duration (r = 0.81, p < 0.01) 
(Figure 4b). MTREX showed a positive correlation with attentional performance in the 
direct spatial span test (r = 0.52, p < 0.05) (Figure 4c), and with better verbal fluency scores 
(r = 0.50, p < 0.05) (Figure 4d). Moreover, MTREX positively correlated with GAF (r = 0.73, 
p < 0.001) (Figure 4e), and correlated negatively with NSS (r = −0.65, p < 0.01) (Figure 4f). 
In addition, ZNF326 negatively correlated with attention in the direct spatial span test (r 
= −0.57, p < 0.01) (Figure 4j); with working memory in the inverse spatial span test (r = 
−0.51, p < 0.05) (Figure 4g); and with emotional recognition scores (r = −0.55, p < 0.05) 
(Figure 4h). Finally, higher ZNF326 correlated with lower GAF (r = −0.49, p < 0.05) (Figure 
4i) and higher NSS (r = 0.52, p < 0.05) (Figure 4j). CDK5RAP3 correlated with GAF (r = 
−0.5, p < 0.05) and NSS (r = 0.47, p < 0.05) (Supplement Figure 2a,b). MYO1B levels were 
Figure 2. Specific proteomic markers of schizophrenia patients non-cannabis users (SCZ/nc). (a) Venn diagram comparing
SCZ/nc to control subjects non-cannabis users (C/nc), control cannabis users (C/c) and schizophrenia patients cannabis
users (SCZ/c). Graphical represent tion of CDK5 (b), LSM2 (c) and YARS2 (d), which were c mmonly der gulated in
SCZ/c as compared to C/nc, C/c and SCZ/nc. ** p < 0.01; versus C/nc; ++ p < 0.01 versus C/c; ## p < 0.01 versus SCZ/nc.
To identify specific protein markers in the ON cells of SCZ/c, the 380 proteins exclu-
sively d regulat d in SCZ/c as compared to C/nc, the 115 proteins d fferently expressed
in SCZ/c as compared to SCZ/nc, and the 154 proteins exclusively differing between
SCZ/c and C/c, were compared (Figure 3a). Seven proteins were commonly deregulated
in these three comparisons; (i) CDK5 regulatory subunit-associated protein 3 (CDKRAP3);
(ii) Haloacid dehalogenase-like hydrolase domain-containing 5 (HDHD5); (iii) Exosome
RNA helicase MTR4 (MTREX); (iv) Unconventional myosin-Ib (MYO1B); (v) 40S ribosomal
protein S20 (RPS20); (vi) Nucleoporin SEH1 (SEH1L), and (vii) DBIRD complex subunit
ZNF326 (ZNF326). CDK5RAP3 was significantly upregulated in SCZ/c as compared to
C/nc, C/c and SCZ/nc (p < 0.001, p < 0.05, p < 0.05, respectively) (Figure 3b). HDHD5
was not significantly altered when the four groups were compared together. MTREX
was downregulated in SCZ/c (p < 0.001) and SCZ/nc (p < 0.05) as compared to C/nc.
SCZ/c showed a significant downregulation in its expression as compared to C/c (p < 0.05)
(Figure 3c). MYO1B was significantly upregulated in SCZ/c as compared to C/nc (p < 0.01)
and C/c and SCZ/nc (p < 0.05) (Figure 3d). RPS20 was downregulated in SCZ/c only, as
compared to non-cannabis users (p < 0.001 vs. C/nc and p < 0.05 vs. SCZ/nc) (Figure 3e).
SEH1L was significantly upregulated in SCZ/c as compared to C/nc (p < 0.01), C/c and
SCZ/nc (p < 0.05) (Figure 3f). Finally, ZNF326 was significantly upregulated in SCZ/c as
compared to C/nc (p < 0.001) and C/c and SCZ/nc (p < 0.05) (Figure 3g).
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to control subjects non-cannabis users (C/nc), schizophrenia patients non-cannabis users (SCZ/nc), and control cannabis
users (C/ ). Graphical representation of CDK5RAP3 (b), MTREX (c), MYO1B (d), RPS20 (e), SEH1L (f), and ZNF326 (g),
which were commonly deregulated in SCZ/c as compared to C/nc, C/c and SCZ/c. Data are represented as the mean ±
minimum to maximum peak intensity. * p < 0.05; ** p < 0.01; *** p < 0001 versus C/nc; + p < 0.05 versus C/c; # p < 0.05;
versus SCZ/nc.
3.4. Correlations between Specific Protein Markers, Cannabis Use and Cognitive Performance
A Spearman correlation plot was designed to evaluate the association between the
expression levels of target proteins identified in SCZ/nc and in SCZ/c with cognitive
performance, cannabis use patterns, and clinical signs in the entire population. For proteins
related to SCZ/nc, the results showed that higher LSM2 expression was correlated with
better GAF (r = 0.50, p < 0.05) and less NSS (r = −0.54, p < 0.05), whereas higher YARS2
levels were associated with better attentional performance in the direct series score test
(r = 0.53, p < 0.05) (Data not shown). For proteins related to SCZ/c, MYO1B negatively
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correlated with plasmatic THC-COOH concentration (r = −0.80, p < 0.05) (Figure 4a), and
ZNF326 positively correlated with cannabis use duration (r = 0.81, p < 0.01) (Figure 4b).
MTREX showed a positive correlation with attentional performance in the direct spatial
span test (r = 0.52, p < 0.05) (Figure 4c), and with better verbal fluency scores (r = 0.50,
p < 0.05) (Figure 4d). Moreover, MTREX positively correlated with GAF (r = 0.73, p < 0.001)
(Figure 4e), and correlated negatively with NSS (r = −0.65, p < 0.01) (Figure 4f). In addition,
ZNF326 negatively correlated with attention in the direct spatial span test (r = −0.57,
p < 0.01) (Figure 4j); with working memory in the inverse spatial span test (r = −0.51,
p < 0.05) (Figure 4g); and with emotional recognition scores (r = −0.55, p < 0.05) (Figure 4h).
Finally, higher ZNF326 correlated with lower GAF (r = −0.49, p < 0.05) (Figure 4i) and
higher NSS (r = 0.52, p < 0.05) (Figure 4j). CDK5RAP3 correlated with GAF (r = −0.5,
p < 0.05) and NSS (r = 0.47, p < 0.05) (Supplement Figure S2a,b). MYO1B levels were
negatively correlated with GAF scores (r = −0.56, p < 0.05) and positively with NSS
(r = 0.48, p < 0.05) (Supplementary Figure S2c,d). Finally, RPS20 was positively associated
with GAF (r = −0.50, p < 0.05) (Supplementary Figure S2e), while SEH1L showed a
significant negative correlation with this parameter (r = 0.48, p < 0.05) (Supplementary
Figure S2f).
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4. Discussion
In this study we revealed a quantitative shared impact of cannabis use and SCZ. These
results are consistent with recent GWAS studies showing a significant common genetic risk
of SCZ and cannabis use [29]. Interestingly, when assessing the exclusively deregulated
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proteins, we observed a functional selectivity among the different groups. Thus, the most
significantly deregulated pathway in C/c was the immune system cascade, while in SCZ/c
metabolism of RNA, cell responses to external stimuli and metabolism of proteins showed
strong and significant alterations. In SCZ/nc, smaller but significant deregulations were
observed in cell cycle, DNA replication and cell responses to external stimuli cascades.
These findings indicate that despite the common proteomic changes induced by cannabis
use and SCZ, there might be specific changes prompted in the proteome depending on
whether these two factors are present together or separately. In fact, when we subtracted
the effect of cannabis comparing both groups of SCZ patients with C/c, we found a more
similar profile between SCZ/nc and C/c, with small deregulations in protein localization
and signal transduction, than in SCZ/c and C/c, which showed larger changes only in
metabolism of RNA. Moreover, when the exclusively deregulated proteins were compared
in both groups of SCZ patients, differences were obtained for metabolism of RNA and
cellular responses to external stimuli. Again, these comparisons revealed functional differ-
ences in the proteomic alterations induced by the presence of SCZ depending on whether
patients use cannabis or not.
Therefore, to identify specific proteins that could be proteomic markers of SCZ with or
without the concomitant use of cannabis, we assessed separately the commonly deregulated
proteins in SCZ/nc and in SCZ/c with respect to all the other groups. In SCZ/nc, we
found three protein markers: CDK5, LSM2 and YARS2. These proteins were significantly
downregulated in SCZ/nc, but not in SCZ/c. CDK5 is a cyclin-dependent kinase that
controls the development of the central nervous system [34]. In the mature brain, it
is associated with cognitive processes [35], and in vitro, it modulates oxidative stress
responses [36]. According to the REACTOME database, it participates in developmental
biology, which functionally differentiates SCZ/nc from SCZ/c. The observed reduction
in CDK5 expression is consistent with previous studies showing a significant decline in
CDK5 expression in postmortem brain samples of antipsychotic-treated SCZ patients,
but not in drug-naïve individuals [37]. Markedly, our data indicate that cannabis use
may counteract the effects of SCZ on CDK5. Further studies may shed light on whether
cannabis use also opposes antipsychotic efficiency through this mechanism. Secondly,
the downregulation of LSM2, which encodes for a key protein of the spliceosome [38],
is in agreement with previously reported global changes in alternative splicing in SCZ
patients [39]. LSM2 participates in metabolism of RNA, which differentiated SCZ/nc from
SCZ/c, and presented a positive correlation with GAF and a negative correlation with NSS,
indicating that it may be relevant for the clinical alterations observed in SCZ. Thirdly, we
show a decrease in YARS2, a tyrosyl-tRNA synthetase located in the mitochondria, involved
in metabolism of proteins, which differentiated SCZ/nc from SCZ/c. Its downregulation
may lead to respiratory chain dysfunctions causing mitochondrial oxidative stress [40],
which has been observed in postmortem brain samples from SCZ patients [41,42]. Moreover,
lower levels of YARS2 could be correlated with worse attention performance, consistent
with previous studies reporting that an oxidative imbalance increases negative symptoms’
severity in SCZ patients [43]. Once more, cannabis use seems to counteract the molecular
changes in YARS2 in ON cells of SCZ/c, hypothetically via CB1 receptors expressed in the
mitochondrial membranes [44], which have been proven to modulate respiration in this
organelle [45].
In SCZ/c, we identified expression level changes in seven proteins: CDK5RAP3,
HDHD5, MYO1B, MTREX, RPS20, SEH1L, and ZNF326. CDK5RAP3, a regulator of CDK5,
was significantly upregulated in SCZ/c with respect to all other groups. It is genetically
associated with SCZ [46], and participates in cell cycle. It modulates hippocampal aging
because its transcriptional upregulation lowers neurogenesis [47]. Higher levels of this pro-
tein were associated with less GAF and more NSS in the entire population. MYO1B, SEH1L
and RPS20 were also deregulated, specifically in SCZ/c, and were associated with clinical
outcomes (GAF and NSS). They are involved in the metabolism of proteins cascade, which
includes the AKT-mTOR pathway that is thought to play a role in the interaction between
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SCZ and cannabinoids exposure in humans [48] and in mice models [24]. In fact, MYO1B,
SEH1L and RPS20 directly or indirectly interact with AKT-mTOR [49–51]. Interestingly, we
found a negative correlation between MYO1B and plasmatic concentrations of THC-COOH
in SCZ/c and C/c. THC-COOH is the last molecule arising from ∆9-tetrahidrocannabinol
degradation [52], which might point to the role of this unconventional myosin in cannabis
metabolism. Finally, MTREX and ZNF326, which are involved in the metabolism of RNA
cascade, were found to be deregulated in SCZ/c as compared to the rest of the groups. In
fact, metabolism of RNA was consistently deregulated in SCZ/c in every functional com-
parison. Although prior studies have found deregulations in ribosomal and RNA-related
proteins in human samples from SCZ patients [53,54], our data revealed functional differ-
ences in metabolism of RNA exclusively linked to the coexistence of cannabis consumption
and SCZ. According to REACTOME, MTREX and ZNF326 are involved in the same step
of pre-mRNA processing prior to protein translation. However, we found that MTREX
was significantly downregulated in SCZ/nc and SCZ/c, while ZNF326 was upregulated in
SCZ/c, but both of these alterations correlated with worse cognitive performance and more
clinical signs of SCZ. Thus, a lower peak intensity of MTREX was associated with worse
spatial attention, verbal fluency, and GAF scores, but with more NSS. On the other hand,
higher peak intensity levels of ZNF326 were related with worse attention, working mem-
ory, emotional recognition, and clinical signs. Moreover, cannabis use duration positively
correlated with ZNF326 expression. These data indicate that either a decrease in MTREX or
an increase in ZNF326 expression may have a negative effect on RNA metabolism, which
could impact neurocognitive functioning.
The results of our study need to be interpreted considering its strengths and limita-
tions. The main strength of our data relies on the translational power of ON cell models
to investigate biomarkers of neuropsychiatric disorders, such as SCZ. In addition, the
evaluation of cannabis’ effects on separate cohorts of SCZ patients is unique, since there is
an absence of studies comparing these populations. The main limitation of our study was
the small number of subjects per group, thus, additional follow-up studies on a larger scale,
including longitudinal and epidemiological studies, will be needed to further corroborate
these findings.
In summary, we revealed a quantitative shared effect of SCZ and cannabis use in
the proteomic profile of ON cells, consistent with the genetic similarities previously de-
scribed [29]. We found that cannabis use in controls has a significant impact on the immune
system, while it alters metabolism of RNA and metabolism of proteins in SCZ patients.
Additionally, SCZ/nc show small but significant differences in cell cycle, DNA replica-
tion, proteins localization and signal transduction. In this group, we identified significant
changes in two functionally relevant proteins (YARS2 and LSM2) associated to attentional
processes, GAF and NSS scores. On the other hand, in ON cells from SCZ/c we found
significant changes in six proteins relevant to clinical scores (MYO1B, MTREX, ZNF326,
RPS20, CDK5RAP3, SEH1L) and two for cannabis use (MYO1B, ZNF326). Moreover, in
SCZ/c, we identified consistent deregulation in metabolism of RNA in every comparison,
and expression levels of MTREX and ZNF326, which take part in this pathway, correlated
with several aspects of cognitive performance.
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